Loading
Adipokines, Inflammation, and Metabolic Diseases / Regulation of Appetite and Obesity · Journal article
iScience · September 9, 2026
Encouraging direction, but not yet definitive.
In a 90-day randomized, double-blind, placebo-controlled trial of 56 adults with obesity, Pep19 10 mg daily reduced central adiposity (android-to-gynoid fat ratio and abdominal skinfold thickness) and improved markers of insulin sensitivity (HbA1c and HOMA-IR reductions) without weight loss. The finding is mechanistically interesting but based on a small sample and surrogate endpoints; replication in larger, longer-term trials is required before clinical application.
Randomized, double-blind, placebo-controlled trial. Adults with obesity. Intervention: Pep19 at 5 mg or 10 mg daily, oral. Compared with: Placebo. n = 56.
Pep19 10 mg reduced central adiposity as measured by android-to-gynoid fat ratio and decreased abdominal skinfold thickness without affecting body weight Glycated hemoglobin (HbA1c) and HOMA-IR were significantly reduced despite unchanged fasting glucose No changes in caloric intake or physical activity were detected during the 90-day intervention period
Surrogate biomarkers used; no assessment of hard clinical outcomes (cardiovascular, mortality, or diabetes incidence) No long-term follow-up data; 90-day duration may not capture sustained effects or adverse events
If confirmed in larger trials, Pep19 could represent a novel approach to improving insulin sensitivity through fat redistribution rather than weight loss, potentially benefiting patients unable to achieve sustained weight reduction. Current evidence is insufficient to guide clinical practice.
A sound but limited randomized controlled trial with a small sample showing a plausible metabolic benefit via redistribution of fat rather than weight loss, requiring confirmation in larger studies.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in larger trials, Pep19 could represent a novel approach to improving insulin sensitivity through fat redistribution rather than weight loss, potentially benefiting patients unable to achieve sustained weight reduction. Current evidence is insufficient to guide clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Whether modulation of adipose tissue distribution alone can improve insulin sensitivity independently of weight loss remains unclear. In this randomized, double-blind, placebo-controlled 90-day trial, we investigated whether adults with obesity could achieve metabolic improvement through modulation of adipose tissue distribution independent of weight loss. Fifty-six participants received oral placebo or Pep19 (5 or 10 mg daily). Regional fat distribution and metabolic parameters were assessed longitudinally. Pep19 at 10 mg reduced central adiposity, as demonstrated by a reduced android-to-gynoid fat ratio and decreased abdominal skinfold thickness, without affecting body weight, caloric intake, or physical activity. Glycated hemoglobin (HbA1c) and HOMA-IR were significantly reduced, despite unchanged fasting glucose, indicating improved insulin sensitivity. These findings suggest that Pep19 promotes favorable changes in adipose tissue distribution accompanied by improvements in insulin sensitivity independent of significant weight loss, supporting further evaluation in larger and longer-term clinical studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.